ADMA Biologics’ (ADMA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of ADMA Biologics (NASDAQ:ADMA) in a research note released on Tuesday, Benzinga reports. HC Wainwright currently has a $7.50 price target on the biotechnology company’s stock, up from their prior price target of $6.00.

A number of other equities analysts have also recently issued reports on the company. Mizuho lifted their target price on ADMA Biologics from $9.00 to $10.00 and gave the stock a buy rating in a report on Friday, March 1st. Cantor Fitzgerald lifted their target price on ADMA Biologics from $6.50 to $8.00 and gave the stock an overweight rating in a report on Thursday, February 29th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Buy and a consensus target price of $7.88.

ADMA Biologics Stock Down 2.1 %

Shares of ADMA stock opened at $6.60 on Tuesday. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $6.76. The stock has a market cap of $1.51 billion, a PE ratio of -50.77 and a beta of 0.43. The business’s fifty day moving average is $5.62 and its 200-day moving average is $4.47. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $73.90 million for the quarter, compared to analysts’ expectations of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. Equities analysts expect that ADMA Biologics will post 0.3 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Steve Elms sold 407,000 shares of ADMA Biologics stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the transaction, the director now owns 3,208,671 shares in the company, valued at $19,925,846.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 639,895 shares of company stock worth $3,927,169. 6.00% of the stock is owned by corporate insiders.

Institutional Trading of ADMA Biologics

A number of institutional investors have recently bought and sold shares of ADMA. Virtu Financial LLC acquired a new stake in ADMA Biologics during the second quarter valued at $34,000. Envestnet Asset Management Inc. acquired a new stake in ADMA Biologics during the first quarter valued at $35,000. Price T Rowe Associates Inc. MD acquired a new stake in ADMA Biologics during the second quarter valued at $35,000. Stephens Consulting LLC acquired a new stake in ADMA Biologics during the third quarter valued at $36,000. Finally, Cerity Partners LLC acquired a new stake in ADMA Biologics during the second quarter valued at $37,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.